

REPORTED SALES vs. PRIOR PERIOD (\$MM)

PHARMACEUTICAL SEGMENT ^{(2) (3)}

IMMUNOLOGY

	2015	2014	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	\$ 1,755	1,547	13.4%	13.4%	-
Intl	708	796	-11.1%	3.1%	-14.2%
WW	2,463	2,343	5.1%	9.9%	-4.8%

REMICADE

US	1,055	997	5.8%	5.8%	-
US Exports ⁽⁴⁾	181	167	8.4%	8.4%	-
Intl	364	446	-18.4%	-6.2%	-12.2%
WW	1,600	1,610	-0.6%	2.8%	-3.4%

SIMPONI / SIMPONI ARIA

US	155	104	49.0%	49.0%	-
Intl	145	155	-6.5%	9.7%	-16.2%
WW	300	259	15.8%	25.5%	-9.7%

STELARA

US	364	279	30.5%	30.5%	-
Intl	185	177	4.5%	22.5%	-18.0%
WW	549	456	20.4%	27.4%	-7.0%

OTHER IMMUNOLOGY

US	-	-	-	-	-
Intl	14	18	-22.2%	-13.7%	-8.5%
WW	14	18	-22.2%	-13.7%	-8.5%

INFECTIOUS DISEASES

US	412	561	-26.6%	-26.6%	-
Intl	563	639	-11.9%	4.2%	-16.1%
WW	975	1,200	-18.8%	-10.2%	-8.6%

EDURANT

US	9	5	80.0%	80.0%	-
Intl	82	76	7.9%	30.6%	-22.7%
WW	91	81	12.3%	33.6%	-21.3%

OLYSIO / SOVRIAD

US	98	291	-66.3%	-66.3%	-
Intl	136	63	*	*	**
WW	234	354	-33.9%	-26.2%	-7.7%

PREZISTA / PREZCOBIX

US	234	214	9.3%	9.3%	-
Intl	193	231	-16.5%	-1.6%	-14.9%
WW	427	445	-4.0%	3.7%	-7.7%

OTHER INFECTIOUS DISEASES

US	71	51	39.2%	39.2%	-
Intl	152	269	-43.5%	-34.5%	-9.0%
WW	223	320	-30.3%	-22.8%	-7.5%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

FIRST QUARTER

NEUROSCIENCE

	2015	2014	% Change		
			Reported	Operational ⁽¹⁾	Currency
US	750	601	24.8%	24.8%	-
Intl	868	1,037	-16.3%	-3.2%	-13.1%
WW	<u>1,618</u>	<u>1,638</u>	-1.2%	7.1%	-8.3%

CONCERTA / METHYLPHENIDATE

US	126	35	*	*	-
Intl	98	115	-14.8%	-3.5%	-11.3%
WW	<u>224</u>	<u>150</u>	49.3%	58.0%	-8.7%

INVEGA

US	94	86	9.3%	9.3%	-
Intl	61	79	-22.8%	-8.7%	-14.1%
WW	<u>155</u>	<u>165</u>	-6.1%	0.7%	-6.8%

INVEGA SUSTENNA / XEPLION

US	228	182	25.3%	25.3%	-
Intl	183	191	-4.2%	12.5%	-16.7%
WW	<u>411</u>	<u>373</u>	10.2%	18.7%	-8.5%

RISPERDAL CONSTA

US	104	106	-1.9%	-1.9%	-
Intl	150	204	-26.5%	-13.0%	-13.5%
WW	<u>254</u>	<u>310</u>	-18.1%	-9.2%	-8.9%

OTHER NEUROSCIENCE

US	198	192	3.1%	3.1%	-
Intl	376	448	-16.1%	-4.5%	-11.6%
WW	<u>574</u>	<u>640</u>	-10.3%	-2.2%	-8.1%

ONCOLOGY

US	334	240	39.2%	39.2%	-
Intl	774	782	-1.0%	15.7%	-16.7%
WW	<u>1,108</u>	<u>1,022</u>	8.4%	21.2%	-12.8%

IMBRUVICA

US	66	6	*	*	-
Intl	50	4	*	*	**
WW	<u>116</u>	<u>10</u>	*	*	**

VELCADE

US	-	-	-	-	-
Intl	339	408	-16.9%	-4.0%	-12.9%
WW	<u>339</u>	<u>408</u>	-16.9%	-4.0%	-12.9%

ZYTIGA

US	253	229	10.5%	10.5%	-
Intl	303	283	7.1%	26.3%	-19.2%
WW	<u>556</u>	<u>512</u>	8.6%	19.2%	-10.6%

OTHER ONCOLOGY

US	15	5	*	*	-
Intl	82	87	-5.7%	10.1%	-15.8%
WW	<u>97</u>	<u>92</u>	5.4%	20.3%	-14.9%

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2015	2014	% Change		
			Reported	Operational ⁽¹⁾	Currency
CARDIOVASCULAR / METABOLISM / OTHER ⁽⁵⁾					
US	1,120	791	41.6%	41.6%	-
Intl	442	504	-12.3%	-0.8%	-11.5%
WW	<u>1,562</u>	<u>1,295</u>	20.6%	25.1%	-4.5%
XARELTO					
US	441	319	38.2%	38.2%	-
Intl	-	-	-	-	-
WW	<u>441</u>	<u>319</u>	38.2%	38.2%	0.0%
INVOKANA / INVOKAMET					
US	266	93	*	*	-
Intl	12	1	*	*	**
WW	<u>278</u>	<u>94</u>	*	*	**
PROCRIPT / EPREX					
US	163	176	-7.4%	-7.4%	-
Intl	106	134	-20.9%	-7.5%	-13.4%
WW	<u>269</u>	<u>310</u>	-13.2%	-7.4%	-5.8%
OTHER					
US	250	203	23.2%	23.2%	-
Intl	324	369	-12.2%	-1.7%	-10.5%
WW	<u>574</u>	<u>572</u>	0.3%	7.1%	-6.8%
TOTAL PHARMACEUTICAL					
US	4,371	3,740	16.9%	16.9%	-
Intl	3,355	3,758	-10.7%	3.7%	-14.4%
WW	<u>\$ 7,726</u>	<u>7,498</u>	3.0%	10.2%	-7.2%

Supplemental Sales Information

	2014				
	Q1	Q2	Q3	Q4	Full Year
INVOKANA / INVOKAMET					
US	93	114	169	193	569
Intl	1	3	5	8	17
WW	<u>94</u>	<u>117</u>	<u>174</u>	<u>201</u>	<u>586</u>
IMBRUVICA					
US	6	33	42	64	145
Intl	4	9	14	28	55
WW	<u>10</u>	<u>42</u>	<u>56</u>	<u>92</u>	<u>200</u>

See footnotes at end of schedule

REPORTED SALES vs. PRIOR PERIOD (\$MM)

	FIRST QUARTER				
	2015	2014	% Change		
			Reported	Operational ⁽¹⁾	Currency
MEDICAL DEVICES ⁽²⁾					
CARDIOVASCULAR CARE					
US	\$ 228	205	11.2%	11.2%	-
Intl	301	336	-10.4%	3.4%	-13.8%
WW	529	541	-2.2%	6.4%	-8.6%
DIABETES CARE					
US	212	192	10.4%	10.4%	-
Intl	272	320	-15.0%	0.6%	-15.6%
WW	484	512	-5.5%	4.2%	-9.7%
DIAGNOSTICS ⁽⁶⁾					
US	-	224	**	**	-
Intl	30	219	-86.3%	-83.5%	-2.8%
WW	30	443	-93.2%	-91.8%	-1.4%
ORTHOPAEDICS					
US	1,309	1,292	1.3%	1.3%	-
Intl	1,019	1,129	-9.7%	2.9%	-12.6%
WW	2,328	2,421	-3.8%	2.1%	-5.9%
SPECIALTY SURGERY / OTHER					
US	417	417	0.0%	0.0%	-
Intl	416	457	-9.0%	3.5%	-12.5%
WW	833	874	-4.7%	1.8%	-6.5%
SURGICAL CARE					
US	543	539	0.7%	0.7%	-
Intl	880	969	-9.2%	3.0%	-12.2%
WW	1,423	1,508	-5.6%	2.3%	-7.9%
VISION CARE					
US	253	286	-11.5%	-11.5%	-
Intl	378	475	-20.4%	-7.5%	-12.9%
WW	631	761	-17.1%	-9.0%	-8.1%
TOTAL MEDICAL DEVICES					
US	2,962	3,155	-6.1%	-6.1%	-
Intl	3,296	3,905	-15.6%	-3.3%	-12.3%
WW	\$ 6,258	7,060	-11.4%	-4.6%	-6.8%

* Percentage greater than 100%

** Not meaningful

(1) Operational growth excludes the effect of translational currency

(2) Unaudited

(3) Prior year amounts have been reclassified to conform to current year product disclosure

(4) Reported as U.S. sales

(5) Previously referred to as Other

(6) Reflects Diagnostics divestiture June 30, 2014